(Q37912228)

25 August 2017

1 reference

title

Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact (English)

1 reference

25 August 2017

1

Julia M L Brotherton

1 reference

25 August 2017

2

Dorota M Gertig

1 reference

25 August 2017

publication date

1 August 2011

1 reference

Expert Review of Anti-infective Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

9

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

627-639

1 reference

Human papillomavirus update with a particular focus on cervical disease

25 August 2017

cites work

1 reference

Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments

21 January 2018

1 reference

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

21 January 2018

1 reference

A review of human carcinogens--Part B: biological agents

21 January 2018

1 reference

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

21 January 2018

1 reference

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

21 January 2018

1 reference

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.

21 January 2018

1 reference

Recurrent respiratory papillomatosis: a review

21 January 2018

1 reference

Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study

21 January 2018

1 reference

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

21 January 2018

1 reference

Human papillomavirus infections among couples in new sexual relationships

21 January 2018

1 reference

HPV - immune response to infection and vaccination

21 January 2018

1 reference

Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins

21 January 2018

1 reference

Human papillomavirus immortalization and transformation functions

21 January 2018

1 reference

Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies

21 January 2018

1 reference

Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer

21 January 2018

1 reference

Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study

21 January 2018

1 reference

Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies

21 January 2018

1 reference

Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies

21 January 2018

1 reference

The 2001 Bethesda System: terminology for reporting results of cervical cytology

21 January 2018

1 reference

Human papillomavirus and cervical cancer

21 January 2018

1 reference

The predicted effect of changes in cervical screening practice in the UK: results from a modelling study

21 January 2018

1 reference

Non-progression of cervical intraepithelial neoplasia estimated from population-screening data

21 January 2018

1 reference

Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer

21 January 2018

1 reference

The psychosocial burden of human papillomavirus related disease and screening interventions.

21 January 2018

1 reference

Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial

21 January 2018

1 reference

Psychological response to cervical screening.

21 January 2018

1 reference

Preterm delivery after surgical treatment for cervical intraepithelial neoplasia

21 January 2018

1 reference

Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis

21 January 2018

1 reference

HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women

21 January 2018

1 reference

Sexual practices, sexually transmitted diseases, and the incidence of anal cancer

21 January 2018

1 reference

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

21 January 2018

1 reference

Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom

21 January 2018

1 reference

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

21 January 2018

1 reference

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

21 January 2018

1 reference

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

21 January 2018

1 reference

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

21 January 2018

1 reference

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

21 January 2018

1 reference

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

Anaphylaxis following quadrivalent human papillomavirus vaccination

21 January 2018

1 reference

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

21 January 2018

1 reference

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

21 January 2018

1 reference

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

21 January 2018

1 reference

A brief history of economic evaluation for human papillomavirus vaccination policy

21 January 2018

1 reference

Voluntary school-based human papillomavirus vaccination: an efficient and acceptable model for achieving high vaccine coverage in adolescents.

21 January 2018

1 reference

Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial

21 January 2018

1 reference

Economic Evaluation of the 7-Vaccine Routine Childhood Immunization Schedule in the United States, 2001

21 January 2018

1 reference

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

21 January 2018

1 reference

Drugs, sex, money and power: an HPV vaccine case study

21 January 2018

1 reference

Mothers' and adolescents' beliefs about risk compensation following HPV vaccination.

21 January 2018

1 reference

Parental attitudes to pre-pubertal HPV vaccination.

21 January 2018

1 reference

Determinants for HPV vaccine uptake in the Netherlands: A multilevel study

21 January 2018

1 reference

Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study

21 January 2018

1 reference

Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis

21 January 2018

1 reference

Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination

21 January 2018

1 reference

Parental response to human papillomavirus vaccine availability: uptake and intentions.

21 January 2018

1 reference

Participation in the decision to become vaccinated against human papillomavirus by California high school girls and the predictors of vaccine status

21 January 2018

1 reference

Financing the delivery of vaccines to children and adolescents: challenges to the current system

21 January 2018

1 reference

Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey

21 January 2018

1 reference

Parents' health beliefs and HPV vaccination of their adolescent daughters

21 January 2018

1 reference

Disparities in how parents are learning about the human papillomavirus vaccine

21 January 2018

1 reference

A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt

21 January 2018

1 reference

Human papillomavirus and cervical cancer: Gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students.

21 January 2018

1 reference

"Is cancer contagious?": Australian adolescent girls and their parents: making the most of limited information about HPV and HPV vaccination.

21 January 2018

1 reference

"I just signed": Factors influencing decision-making for school-based HPV vaccination of adolescent girls.

21 January 2018

1 reference

HPV information needs, educational messages and channel of delivery preferences: views from developing country with multiethnic populations

21 January 2018

1 reference

Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia

21 January 2018

1 reference

A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.

21 January 2018

1 reference

Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries.

21 January 2018

1 reference

The predicted impact of vaccination on human papillomavirus infections in Australia

21 January 2018

1 reference

Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.

21 January 2018

1 reference

Modeling cervical cancer prevention in developed countries

21 January 2018

1 reference

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

21 January 2018

1 reference

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India

21 January 2018

1 reference

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

21 January 2018

1 reference

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

21 January 2018

1 reference

Chapter 16: HPV vaccines in immunocompromised women and men.

21 January 2018

1 reference

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

21 January 2018

1 reference

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

21 January 2018

1 reference

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

21 January 2018

1 reference

Human papillomavirus vaccine coverage

21 January 2018

1 reference

Human papillomavirus vaccine coverage

21 January 2018

1 reference

The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change

21 January 2018

1 reference

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

21 January 2018

1 reference

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

21 January 2018

1 reference

New technologies in cervical cancer screening

21 January 2018

1 reference

HPV screening for cervical cancer in rural India

21 January 2018

1 reference

Expansion of cancer care and control in countries of low and middle income: a call to action

21 January 2018

1 reference

Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement

21 January 2018

1 reference

Prophylactic HPV vaccines: the Finnish perspective

21 January 2018

1 reference

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

21 January 2018

1 reference

The India HPV-vaccine suspension

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERI.11.78

1 reference

25 August 2017

1 reference